A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
Oncologist
; 29(4): 324-331, 2024 Apr 04.
Article
in En
| MEDLINE
| ID: mdl-37950901
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
Limits:
Humans
Language:
En
Journal:
Oncologist
Journal subject:
NEOPLASIAS
Year:
2024
Type:
Article
Affiliation country:
United States